Healthcare and an ageing population

investment viewpoints

Healthcare and an ageing population

Meret Gaugler - Co-Portfolio Manager

Meret Gaugler

Co-Portfolio Manager

The median age of people worldwide is steadily climbing higher. The United Nations predicts there will be over 2 billion people aged 60 years or over by 2050, up from 962 million in 2017.

In fact, the age group of retirees is growing at a faster pace than any younger age group. This has far-reaching consequences for society and our economies, creating opportunities for companies and investors, but also new challenges. 

Research conducted by the European Commission (EC) suggest that the healthcare sector is one with ‘high growth’ potential as a consequence of this demographic shift. Two-thirds of Europe’s healthcare budget or over 300bn EUR is already spent on patients aged 50 or over and increasing steadily.  By 2025, the EC expects health spending for this demographic to total three-quarters of all health spending, worth 465bn EUR.

The reason is that many costly diseases are related to age. Among them diabetes, certain types of cancer, heart failure or memory loss. At first glance, it makes sense to conclude that cancer drugs and nursing homes specializing in dementia care have a promising economic future.

New challenges require new solutions and healthcare is a key area where the urgency of rising costs spurs a great number of exciting innovations and investment opportunities.

However, it is not enough for companies to simply latch onto the ageing demographic trend to tap into a sustainable growth opportunity. While today’s retirees are powerful spenders, the brunt of the cost raked up on healthcare over the course of a person’s life is not coming out of their own pocket. The bill is picked up by insurance companies and – to a greater extent – governments. And governments are starting to crack under the increasing cost burden. In a few years’ time, they might simply have the money to care for an Alzheimer’s patient the way we are striving to do today.

In recent years, this discussion has started to move into the limelight. Just think of the ongoing public and highly politicized debate in the USA regarding the price of prescription drugs, a stone kicked lose by Hilary Clinton when she was running for president back in 2015. While we are not sure that current reform proposals on drug pricing will end up moving the needle if the government wants to tackle overall healthcare cost, public uproar has at least shown that the subject is close to heart to the electorate.

What we do view as a given is that there will be increasing pushback on adding to the already high burden of cost borne by the healthcare system. In fact, our own measure of innovation has always been based not only on the clinical benefit to the patient, but also on a company’s capacity and focus on reducing overall cost and reducing inequalities in accessibility. Simply put, we are looking for drugs that let a patient cut out other treatments or that delays or prevents the onset of a costly disease, all while being accessible to as many people as possible. 

We think this ties in with our broader strategy. We are looking to invest in companies that have staying power over the long run. High quality companies that create value for themselves and their shareholders. Companies that avoid pitfalls and risks that are tolerated a little less each day, such as treating their employees or  less fortunate patient groups with contempt. And companies that have come up with means to meet some of the challenges associated with megatrends such as an ageing population – in the case of an ageing population first and foremost rising healthcare costs. 

In our view, one way to reduce cost on prescription drugs is to make treatments more targeted. By making sure a drug is given only to patients in which the likelihood of it working is high. We think drug manufacturers are increasingly likely only to get paid if the drug does perform in a patient or – to take it one step further – be paid in installments, a bit like leasing a car. This stands in stark contrast to large blockbuster drugs of the past that tended to be handed out without asking too many questions.

However, taking personalized therapies to the extreme may not always be the ideal solution either. Tailoring a treatment to a patient’s individual genetic makeup, for example, often introduces waiting times, costs and high hurdles on access and affordability.

This is why we remain on the lookout for those companies capable of innovating with a clear focus on the patient, the overall cost and on accessibility.

An ageing population is one of today’s megatrends that is forcing us to rethink a number of established norms.  New challenges require new solutions and healthcare is a key area where the urgency of rising costs spurs a great number of exciting innovations and investment opportunities. 

important information.

For professional investor use only. 
This document is issued by Lombard Odier Asset Management (Europe) Limited, authorised and regulated by the Financial Conduct Authority (the “FCA”), and entered on the FCA register with registration number 515393
Lombard Odier Investment Managers (“LOIM”) is a trade name.
This document is provided for informational purposes only and does not constitute an offer or a recommendation to purchase or sell any security or service. It is not intended for distribution, publication, or use in any jurisdiction where such distribution, publication, or use would be unlawful. This document does not contain personalized recommendations or advice and is not intended to substitute any professional advice on investment in financial products. Before entering into any transaction, an investor should consider carefully the suitability of a transaction to his/her particular circumstances and, where necessary, obtain independent professional advice in respect of risks, as well as any legal, regulatory, credit, tax, and accounting consequences. This document is the property of LOIM and is addressed to its recipients exclusively for their personal use. It may not be reproduced (in whole or in part), transmitted, modified, or used for any other purpose without the prior written permission of LOIM. The contents of this document are intended for persons who are sophisticated investment professionals and who are either authorised or regulated to operate in the financial markets or persons who have been vetted by LOIM as having the expertise, experience and knowledge of the investment matters set out in this document and in respect of whom LOIM has received an assurance that they are capable of making their own investment decisions and understanding the risks involved in making investments of the type included in this document or other persons that LOIM has expressly confirmed as being appropriate recipients of this document. If you are not a person falling within the above categories you are kindly asked to either return this document to LOIM or to destroy it and are expressly warned that you must not rely upon its contents or have regard to any of the matters set out in this document in relation to investment matters and must not transmit this document to any other person. This document contains the opinions of LOIM, as at the date of issue. The information and analysis contained herein are based on sources believed to be reliable. However, LOIM does not guarantee the timeliness, accuracy, or completeness of the information contained in this document, nor does it accept any liability for any loss or damage resulting from its use. All information and opinions as well as the prices indicated may change without notice. Neither this document nor any copy thereof may be sent, taken into, or distributed in the United States of America, any of its territories or possessions or areas subject to its jurisdiction, or to or for the benefit of a United States Person. For this purpose, the term "United States Person" shall mean any citizen, national or resident of the United States of America, partnership organized or existing in any state, territory or possession of the United States of America, a corporation organized under the laws of the United States or of any state, territory or possession thereof, or any estate or trust that is subject to United States Federal income tax regardless of the source of its income.
Source of the figures: Unless otherwise stated, figures are prepared by LOIM.
Although certain information has been obtained from public sources believed to be reliable, without independent verification, we cannot guarantee its accuracy or the completeness of all information available from public sources.
Views and opinions expressed are for informational purposes only and do not constitute a recommendation by LOIM to buy, sell or hold any security. Views and opinions are current as of the date of this presentation and may be subject to change. They should not be construed as investment advice.
No part of this material may be (i) copied, photocopied or duplicated in any form, by any means, or (ii) distributed to any person that is not an employee, officer, director, or authorised agent of the recipient, without Lombard Odier Asset Management (Europe) Limited prior consent. In the United Kingdom, this material is a financial promotion and has been approved by Lombard Odier Asset Management (Europe) Limited which is authorised and regulated by the Financial Conduct Authority.
©2019 Lombard Odier IM. All rights reserved.